Skip to main content

Table 2 Transition probabilities based on logit model

From: Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD

CGI-S health states CGI-S health states in Subsequent Week
Normal Mild Moderate Severe
Stimulants only (mean SE)
Normal 0.759 (0.056) 0.238 (0.055) 0.003 (0.001) 0.000 (0.000)
Mild 0.081 (0.013) 0.826 (0.017) 0.093 (0.014) 0.000 (0.000)
Moderate 0.002 (0.001) 0.192 (0.015) 0.801 (0.015) 0.004 (0.003)
Severe 0.000 (0.000) 0.000 (0.000) 0.236 (0.068) 0.763 (0.068)
Combined GXR + stimulants (mean SE)
Normal 0.766 (0.041) 0.231 (0.041) 0.003 (0.001) 0.000 (0.000)
Mild 0.112 (0.014) 0.817 (0.016) 0.070 (0.011) 0.000 (0.000)
Moderate 0.003 (0.001) 0.258 (0.019) 0.737 (0.019) 0.003 (0.001)
Severe 0.000 (0.000) 0.000 (0.000) 0.361 (0.102) 0.550 (0.102)
  1. CGI-S Clinical Global Impression-Severity, GXR guanfacine extended release, SE standard error